Comments

Nuvectis Pharma

NVCTNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$6.77
-0.13-1.88%
At Close: -
$7.10
0.334.87%
After Hours: 7:39 PM EDT
15 minutes delayed
Nuvectis Pharma (NVCT) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$21.00
Lowest Price Target1
$21.00
Consensus Price Target1
$21.00

Nuvectis Pharma (NASDAQ:NVCT) Stock, Analyst Ratings, Price Targets, Forecasts

Nuvectis Pharma Inc has a consensus price target of $21 based on the ratings of 2 analysts. The high is $21 issued by HC Wainwright & Co. on May 8, 2024. The low is $21 issued by HC Wainwright & Co. on May 8, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on May 8, 2024, September 15, 2023, and March 7, 2023, respectively. With an average price target of $21 between HC Wainwright & Co., there's an implied 195.77% upside for Nuvectis Pharma Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Ladenburg Thalmann

1calculated from analyst ratings

Analyst Ratings for Nuvectis Pharma

Buy NowGet Alert
05/08/2024Buy Now195.77%HC Wainwright & Co.
Joseph Pantginis
 → $21ReiteratesBuy → BuyGet Alert
09/15/2023Buy Now195.77%HC Wainwright & Co.
Joseph Pantginis
 → $21ReiteratesBuy → BuyGet Alert
03/07/2023Buy Now195.77%HC Wainwright & Co.
Joseph Pantginis
 → $21Reiterates → BuyGet Alert
02/10/2023Buy Now195.77%HC Wainwright & Co.
Joseph Pantginis
 → $21Reiterates → BuyGet Alert
07/13/2022Buy Now195.77%Ladenburg Thalmann
Aydin Huseynov
 → $21Initiates → BuyGet Alert
05/10/2022Buy Now195.77%HC Wainwright & Co.
Joseph Pantginis
$14 → $21MaintainsBuyGet Alert
03/02/2022Buy Now97.18%HC Wainwright & Co.
Joseph Pantginis
 → $14Initiates → BuyGet Alert

FAQ

Q

What is the target price for Nuvectis Pharma (NVCT) stock?

A

The latest price target for Nuvectis Pharma (NASDAQ:NVCT) was reported by HC Wainwright & Co. on May 8, 2024. The analyst firm set a price target for $21.00 expecting NVCT to rise to within 12 months (a possible 195.77% upside). 2 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Nuvectis Pharma (NVCT)?

A

The latest analyst rating for Nuvectis Pharma (NASDAQ:NVCT) was provided by HC Wainwright & Co., and Nuvectis Pharma reiterated their buy rating.

Q

When was the last upgrade for Nuvectis Pharma (NVCT)?

A

There is no last upgrade for Nuvectis Pharma

Q

When was the last downgrade for Nuvectis Pharma (NVCT)?

A

There is no last downgrade for Nuvectis Pharma.

Q

When is the next analyst rating going to be posted or updated for Nuvectis Pharma (NVCT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nuvectis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nuvectis Pharma was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.

Q

Is the Analyst Rating Nuvectis Pharma (NVCT) correct?

A

While ratings are subjective and will change, the latest Nuvectis Pharma (NVCT) rating was a reiterated with a price target of $21.00 to $21.00. The current price Nuvectis Pharma (NVCT) is trading at is $7.10, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch